SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN W. who wrote (3175)12/8/1997 1:53:00 AM
From: George T. Santamaria  Read Replies (1) of 6136
 
<In a recent tech letter, I read that Glaxo was not impressed with the 70% response
to VX-478 nad was planning to withdraw from the collaboration.>

This comes as good news to us AGPH longs -- just after someone tries to discredit AGPH's efforts for Viracept.

Again, if the story about Glaxo and VRTX is true, I would like to know what letter it was and get a transcript. It would make it all the more believable to others on this thread.

At least it would be better than thinking that I am witnessing a lying contest.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News